Organonitrogen Compounds
Medchemexpress LLC Oxybuprocaine hydrochloride | 5987-82-6 | MFCD00012512 | 344.88 g/mol | C17H29ClN2O3 | 10 MG
Oxybuprocaine hydrochloride is a short-acting ester local anesthetic used topically to produce surface anesthesia by reversibly blocking voltage-gated sodium channels and preventing propagation of painful nerve impulses in ocular tissues. It is intended for research and analytical applications requiring a topical anesthetic agent.
- Short-acting ester local anesthetic for topical applications.
- Reversibly blocks voltage-gated sodium channels to prevent nerve impulse propagation.
- Suitable for ophthalmic and otolaryngologic research applications.
- HCl salt form with CAS 5987-82-6 and molecular weight 344.88 g/mol.
- Supplied in a 10 MG research pack suitable for analytical and preclinical use.
Accela Chembio Inc 3-(dimethylamino)-1-(2-thienyl)-1-propanol | 5g | 13636-02-7 | MFCD09701963 | 97+% | Shelf Life: 1260 Days | Light Sensitive
3-(dimethylamino)-1-(2-thienyl)-1-propanol | 5g | 13636-02-7 | MFCD09701963 | 97+% | Shelf Life: 1260 Days | Light Sensitive
Accela Chembio Inc (s)-(-)-3-(n-methylamino)-1-(2-thienyl)-1-propanol | 5g | 116539-55-0 | MFCD07357308 | 97+% | Shelf Life: 1620 Days | Light Sensitive/n2/+4
(s)-(-)-3-(n-methylamino)-1-(2-thienyl)-1-propanol | 5g | 116539-55-0 | MFCD07357308 | 97+% | Shelf Life: 1620 Days | Light Sensitive/n2/+4
Accela Chembio Inc (1s | 2s)-(-)-1 | 2-diphenylethylenediamine | 25g | 29841-69-8 | MFCD00082751 | 97+% | Shelf Life: 540 Days | Air Sensitive/+4
(1s | 2s)-(-)-1 | 2-diphenylethylenediamine | 25g | 29841-69-8 | MFCD00082751 | 97+% | Shelf Life: 540 Days | Air Sensitive/+4
eMolecules 387350-88-1 | N-(Piperid-4-yl)-3-(trifluoromethylsulphonyl)aniline | Apollo Scientific | MFCD01319328 | 308.320 | C12H15F3N2O2S | 97.000 | FC(F)(F)S(=O)(=O)c1cccc(NC2CCNCC2)c1 | 1g | 562445153
N-(Piperid-4-yl)-3-(trifluoromethylsulphonyl)aniline | Apollo Scientific | 387350-88-1 | MFCD01319328 | 308.320 | C12H15F3N2O2S | 97.000 | FC(F)(F)S(=O)(=O)c1cccc(NC2CCNCC2)c1 | 1g | 562445153
STA PHARMACEUTICAL US LLC 2-(Fmoc-amino)-3-(1-Boc-3-piperidyl)propanoic Acid | 50 g | CAS 457060-97-8 | MDL MFCD02683129
2-(Fmoc-amino)-3-(1-Boc-3-piperidyl)propanoic Acid is a Amino Acid reagent (Subcategory: Unusual AA) sold by WuXi TIDES. Offered in 50 g. Store at 4 °C. SDS available for reference.
Specifications
- CAS: 457060-97-8
- MDL: MFCD02683129
- InChIKey: WPCUPMFUJBWUFE-UHFFFAOYSA-N
- Molecular Weight: 494.588
- Molecular Formula: C28H34N2O6
- Purity: ≥95%
- Container Type: 250 mL HDPE
- Pack Size: 50 g
- Net Weight: 50 g
- Gross Weight: 89.8 g
- Commodity Code: 29333999
- Country Of Origin: China
- IUPAC: 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(1-(tert-butoxycarbonyl)piperidin-3-yl)propanoic acid
- SMILES: CC(OC(N1CCCC(CC(C(O)=O)NC(OCC2C3=CC=CC=C3C4=CC=CC=C42)=O)C1)=O)(C)C
Medchemexpress LLC Teneligliptin hydrobromide | 906093-29-6 | 99.8% | 628.86 | 1 ML
Teneligliptin hydrobromide is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor, demonstrating IC50s of 0.37 nM for human DPP-4 and 0.29 nM for rat DPP-4. This compound improves blood glucose levels and is utilized in research pertaining to type 2 diabetes mellitus.
- Prevents activation of the NLRP3 inflammasome and associated injury.
- Protects against hypoxia/reoxygenation-induced endothelial cell injury by reducing reactive oxygen species.
- Inhibits inflammation and apoptosis induced by doxorubicin.
- Ameliorates diabetic polyneuropathy and enhances pancreatic β-cell volume and insulin secretion.
- Attenuates myocardial hypertrophy, injury, and inflammatory response in diabetic models.
- Prevents obesity and obesity-related manifestations by boosting energy expenditure.
eMolecules 863548-52-1 | (1-Methyl-1H-pyrazol-5-yl)methylamine | Combi-Blocks | MFCD03419808 | 111.148 | C5H9N3 | 98.000 | Cn1nccc1CN | 5g | 232323597
(1-Methyl-1H-pyrazol-5-yl)methylamine | Combi-Blocks | 863548-52-1 | MFCD03419808 | 111.148 | C5H9N3 | 98.000 | Cn1nccc1CN | 5g | 232323597
Medchemexpress LLC Pentanamide, 2-amino-4-methyl-, hydrochloride (1:1), (2S)- | 10466-61-2 | MFCD00013012 | 97.0% | 166.65 g·mol⁻¹ | C6H15ClN2O | 25 G
L-Leucinamide hydrochloride is the hydrochloride salt of L-leucinamide, an amino acid derivative reported to have anti-inflammatory properties. The product is supplied as a solid for research use, with specified purity and recommended storage conditions.
- Hydrochloride salt, solid form.
- Purity 97.0% (NMR).
- Molecular formula C6H15ClN2O, molecular weight 166.65 g·mol⁻¹.
- CAS number 10466-61-2.
- Packaging: 25 g; recommended storage: powder at -20°C for up to 3 years or 4°C for up to 2 years.
Medchemexpress LLC (S)-tomoxetine hydrochloride | 82857-39-4 | MFCD11035876 | 99.8% | 291.82 g/mol | C17H22ClNO | 10 MG
(S)-Tomoxetine hydrochloride is the S-enantiomer of tomoxetine supplied as a white to off-white solid for research and analytical applications. It is an isomer of a norepinephrine reuptake inhibitor and is reported to inhibit norepinephrine reuptake with a Ki of 16.8 nM; not for human use.
- High purity: 99.8%.
- Appearance: white to off-white solid.
- Reported activity: norepinephrine reuptake inhibition (Ki = 16.8 nM).
- Solubility: DMSO 100 mg/mL (requires ultrasonic).
- Recommended storage: powder -20 °C (up to 3 years) or 4 °C (up to 2 years).
- Available pack sizes: 5 MG, 10 MG, larger sizes by quote.
Medchemexpress LLC Norfluoxetine hydrochloride | 57226-68-3 | MFCD00078972 | 99.6% | 331.76 | 50 MG
Norfluoxetine hydrochloride is an active N-demethylated metabolite of Fluoxetine. Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor that is metabolized to Norfluoxetine hydrochloride by cytochrome P450 (CYP) 2D6, CYP2C19, and CYP3A4. Norfluoxetine hydrochloride inhibits 5-HT uptake and inhibits CaV3.3 T current (IC50 = 5 μM). It also has anticonvulsant activity.
- Inhibits 5-HT uptake.
- Inhibits CaV3.3 T current (IC50 = 5 μM).
- Exhibits anticonvulsant activity.
- Pretreatment with Norfluoxetine hydrochloride (20 mg/kg s.c.) significantly increases both the rate and duration of survival, demonstrating a significant protective effect against Pentylenetetrazol-induced epilepsy.